BRIEF-Libtayo Plus Chemotherapy Results At Five Years Reinforce Significant And Durable Improvements In Survival

Reuters
Sep 09
BRIEF-Libtayo Plus Chemotherapy Results At Five Years Reinforce Significant And Durable Improvements In Survival

Sept 9 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:

  • LIBTAYO® (CEMIPLIMAB) PLUS CHEMOTHERAPY RESULTS AT FIVE YEARS REINFORCE SIGNIFICANT AND DURABLE IMPROVEMENTS IN SURVIVAL OUTCOMES FOR ADVANCED NON-SMALL CELL LUNG CANCER

  • REGENERON PHARMACEUTICALS INC - LIBTAYO PLUS CHEMOTHERAPY SHOWS 19.4% FIVE-YEAR SURVIVAL RATE

Source text: ID:nGNX8vPSPz

Further company coverage: REGN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10